| Medical and Health Sciences | Lifetime | 353 | FI 3 | 99.98 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 12 | FI 1 | 99.95 |
| Molecular Biology | Lifetime | 828 | FI 6 | 99.56 |
| Medical Physiology | Lifetime | 371 | FI 2 | 99.39 |
| Cardiology and Cardiovascular Medicine | Lifetime | 387 | FI 1 | 99.50 |
| Surgery | Lifetime | 744 | FI 4 | 99.31 |
| Genetics | Lifetime | 435 | FI 7 | 98.98 |
| Epidemiology | Lifetime | 858 | FI 6 | 98.84 |
| Genetics | 2021-2025 | 213 | FI 3 | 94.42 |
| Molecular Biology | 2021-2025 | 939 | FI 5 | 94.69 |
| Medical Physiology | 2021-2025 | 782 | FI 8 | 87.25 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 7 | FI 1 | 99.95 |
| Metabolism, Diabetes, and Cancer | Lifetime | 9 | FI 1 | 99.89 |
| Diet and metabolism studies | Lifetime | 62 | FI 2 | 99.82 |
| Cardiovascular Function and Risk Factors | Lifetime | 74 | FI 1 | 99.84 |
| Diet, Metabolism, and Disease | Lifetime | 36 | FI 2 | 99.68 |
| Adipose Tissue and Metabolism | Lifetime | 90 | FI 1 | 99.70 |
| Diabetes Treatment and Management | Lifetime | 47 | FI 1 | 99.75 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 49 | FI 1 | 99.68 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 50 | FI 1 | 99.38 |
| Genetic Associations and Epidemiology | Lifetime | 72 | FI 2 | 99.40 |
| Lipoproteins and Cardiovascular Health | Lifetime | 94 | FI 2 | 99.47 |
| Pancreatic function and diabetes | Lifetime | 173 | FI 3 | 99.34 |
| Liver Disease Diagnosis and Treatment | Lifetime | 401 | FI 4 | 99.42 |
| Diabetes and associated disorders | Lifetime | 162 | FI 8 | 99.11 |
| Diabetes Management and Research | Lifetime | 166 | FI 6 | 99.26 |
| Lipid metabolism and disorders | Lifetime | 60 | FI 4 | 98.99 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 84 | FI 2 | 98.65 |
| Pharmacology and Obesity Treatment | Lifetime | 86 | FI 3 | 98.78 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 661 | FI 8 | 97.04 |
| Cardiovascular Disease and Adiposity | Lifetime | 568 | FI 15 | 97.26 |
| Lipid metabolism and biosynthesis | Lifetime | 435 | FI 11 | 96.28 |
| Regulation of Appetite and Obesity | Lifetime | 984 | FI 4 | 95.00 |
| Genetic Associations and Epidemiology | 2021-2025 | 78 | FI 3 | 97.78 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 93 | FI 2 | 96.68 |
| Adipose Tissue and Metabolism | 2021-2025 | 456 | FI 4 | 91.79 |
| Nutrition, Genetics, and Disease | 2021-2025 | 194 | FI 2 | 86.58 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 627 | FI 10 | 89.52 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 631 | FI 8 | 88.42 |
| Fatty Acid Research and Health | 2021-2025 | 522 | FI 6 | 77.71 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 806 | FI 1 | 61.36 |
| Lipid metabolism and biosynthesis | 2021-2025 | 984 | FI 7 | 60.42 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 695 | FI 3 | 60.47 |